June 30 June 30
------- -------
2009 2008* 2009 2008*
---- ---- ---- ----
Revenue, net
Actimmune $7,110 $7,296 $13,142 $15,792
Collaboration revenue 818 818 1,636 1,636
--- --- ----- -----
Total revenue, net 7,928 8,114 14,778 17,428
Costs and expenses:
Cost of goods sold 1,860 2,492 4,718 5,863
Research and development 22,930 25,395 47,357 52,410
General and administrative 8,519 7,091 16,995 14,539
Acquired research and
development milestone - - 13,500 -
Restructuring charges 127 - 740 -
--- --- --- ---
Total costs and expenses 33,436 34,978 83,310 72,812
Loss from operations (25,508) (26,864) (68,532) (55,384)
Interest income 498 1,272 1,167 3,432
Interest expense (2,487) (3,657) (5,220) (7,096)
Loss on extinguishment of debt (9,540) (1,294) (9,540) (1,294)
Other income (expense) 377 987 5,647 1,268
--- --- ----- -----
Loss from continuing operations
before income taxes (36,660) (29,556) (76,478) (59,074)
Income tax expense/(benefit) - - 2,194 (325)
--- --- ----- ----
Loss from conti
'/>"/>SOURCE InterMune, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Related biology technology :1.
InterMune to Release Second Quarter Financial Results on August 62.
InterMune to Present at Goldman Sachs Healthcare Conference3.
InterMune Reports First Quarter 2009 Financial Results and Business Highlights4.
InterMune to Release First Quarter Financial Results on April 305.
InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 256.
InterMune to Present at Canaccord Adams Hepatitis C Conference7.
InterMune to Present at Citis 4th Annual Biotech Day8.
InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting9.
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights10.
InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 2611.
InterMune Announces Issuance of U.S. Patent for ITMN-191